
Overview
Fusiomica is a protein engineering company specializing in the design of de novo mini-protein binders using advanced generative AI algorithms. They produce ultra-stable, high-affinity proteins that can target disease sites inaccessible to traditional antibodies, offering cost-effective imaging probes, biopharmaceuticals, and diagnostic reagents. The company partners with pharmaceutical, biotech, and diagnostic organizations to create bespoke binders and deliver experimentally validated constructs.
Financials
Financial insight
- The statement flags a going concern risk.
Filing timeliness
The financial statement for 2025 was filed on time.
- 202501/07/2026
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Offer
- Protein design
- Binder discovery
- Protein optimisation
- Experimental validation
- Diagnostic reagents
Websites
- fusiomica.comFusiomica | AI-designed proteins for a new era of medicine
Job offers
The company has its own careers page: fusiomica.com.
Authorized Representatives
Manner of representation
Each member of the management board is authorized to make declarations on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Michał Biśta age 42 | 50 | $675.31 | 49.0196% |
Mark Mcalister | 50 | $675.31 | 49.0196% |
Fundacja Rodzinna Filip Stachura | 1 | $13.51 | 0.9804% |
Fundacja Rodzinna P89 | 1 | $13.51 | 0.9804% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2025-01-01.
31 1090 1665 0000 0001 6067 8992
91 1090 1665 0000 0001 6809 7345
16 1090 1665 0000 0001 6449 0877
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Mar 26, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $20,562$20,562 | Marszałek Województwa Małopolskiego | |
| Feb 16, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $33,741$33,741 | Fundacja Startup Hub Poland | |
| Apr 29, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $1,331$1,331 | Instytut Podstawowych Problemów Techniki Polskiej Akademii Nauk |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Fly-Gen sp. z o.o. | $45,325.87 | fly-gen.pl | ||
| Thesybin Labs P.S.A. | $8,297.34 | thesybin.pl | ||
| Oncotherics Poland S.A. | $7,565.33 | oncotherics.com | ||
| Bioinfo Capital sp. z o.o. | $7,450.04 | bioinfo.pl | ||
| Microbiota Med sp. z o.o. | $7,423.69 | microbiota-med.com | ||
| Poltiss sp. z o.o. | $3,843.72 | poltiss.com | ||
| Synerga.Fund S.A. | $3,772.65 | synergafund.com.pl | ||
| Spinbionic sp. z o.o. | $3,516.36 | spinbionic.com | ||
| Refoldit sp. z o.o. | $2,586.64 | refoldit.com | ||
| Bioinfobank S.A. | $688.06 | bioinfobank.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-04-16 | Share capital increase (5,000.00 PLN → 5,100.00 PLN) | |
| 2024-12-19 | Entered in the register |
FAQ
Last updated: 2026-07-04